Literature DB >> 23866873

Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema.

Florence Brunet-Possenti, Olivier Hermine, Eduardo Marinho, Béatrice Crickx, Vincent Descamps.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23866873     DOI： 10.1016/j.jaad.2013.01.028

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  6 in total

Review 1.  [Scleromyxedema].

Authors:  M Neufeld; C Sunderkötter; R K C Moritz
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

Review 2.  New insights on scleromyxedema.

Authors:  Laura Atzori; Caterina Ferreli; Franco Rongioletti
Journal:  J Scleroderma Relat Disord       Date:  2019-01-29

3.  Scleromyxedema, a therapeutic dilemma.

Authors:  Julio Cesar Salas-Alanis; Brayant Martinez-Jaramillo; Minerva Gomez-Flores; Jorge Ocampo-Candiani
Journal:  Indian J Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.494

4.  A case of scleromyxedema responding to lenalidomide and dexamethasone.

Authors:  Sweta Rambhia; Kinjal Rambhia; Amit Gulati; Nirmal Raut
Journal:  Indian Dermatol Online J       Date:  2017 Jan-Feb

Review 5.  Cutaneous manifestations of monoclonal gammopathy.

Authors:  Jean-Sebastien Claveau; David A Wetter; Shaji Kumar
Journal:  Blood Cancer J       Date:  2022-04-11       Impact factor: 11.037

6.  Early onset of scleromyxedema Arndt-Gottron associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins.

Authors:  Asma Kefi; Fatima Jaziri; Khaoula Ben Abdelghani; Sami Turki
Journal:  Clin Case Rep       Date:  2022-08-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.